Clinical Trial Detail

NCT ID NCT02286687
Title Study of the PARP Inhibitor BMN 673 in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Talazoparib

Age Groups: adult

Additional content available in CKB BOOST